Heart Failure

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

SGLT2 inhibitors, ARNIs, and MRAs were associated with a significant decrease in hospital admission for heart failure.

This risk also increased with age and was amplified in patients with HCV compared to patients without HCV.

Dr. Thosani discusses the convergence of technology and physiology, treatment advancements, and virtual medicine capabilities in the field of heart arrhythmia.

In this episode of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, provide a recap of the European Society of Cardiology Congress 2022. This recap begins with a discussion on the results of the phase 3 DELIVER trial, in which Vaduganathan served as an investigator, the ADVOR trial, and REVIVED.

These reductions were only observed in short-term follow-up and were driven by early reductions within 12 months of telemedicine intervention.

The mean LDL-C level among US young adults was 104.9 mg/dL In 2015-2020.

A lower SPPB score was associated with greater risk of composite and individual CVD outcomes.

Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure.

Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.

The treatment strategy led to lower risk of major adverse cardiovascular events than usual care in older patients with recent myocardial infarction.

The scientific statement reviews symptoms associated with ACS, heart failure, valvular disorders, stroke, rhythm disorders, and peripheral vascular disease.

An analysis of DAPA-HF provides insight into the effects of dapagliflozin use on the trial's primary outcome based on iron status at baseline and also sheds light on the impact of dapagliflozin use on iron status at 12 months.

The age-adjusted mortality rates for heart failure in young adults increased from 2.36 in 1999 to 3.16 in 2019.

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost of cardiovascular disease and the role of prevention.

In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.

Early follow-up in patients with COPD led to lower rates of readmissions at 90 days, while patients with CHF saw lower 90-day mortality.

Women show significantly lower risk of first, recurrent life-threatening VTA events than men, while it is more pronounced in patients with NICM.

Rivaroxaban monotherapy was associated with a 38% lower risk of total cardiovascular and bleeding events.

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.

The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.

Both exogenous hyperthyroidism and exogenous hypothyroidism were associated with increased risk of cardiovascular mortality.

Aortic sclerosis, trace or mild aortic regurgitation, and mild mitral regurgitation each had significant associations with CV risk.

The study authors used data from Medicare beneficiaries who survived a heart attack between 1995 and 2019.